TargetMol

Dalfopristin (mesylate) (112362-50-2 free base)

Product Code:
 
TAR-T22707
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T22707-1mg1mg£454.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22707-5mg5mg£1,315.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Dalfopristin (mesylate) is a streptogramin antibiotic and a 50S ribosome inhibitor. Streptogramins are produced by a variety of Streptomyces sp as a mixture (ratio of 7:3) of two chemically unrelated compounds, type A and B. Dalfopristin, the type A Streptogramin is often combined with type B streptogramin antibiotic, quinupristin, to produce Quinupristin-Dalfopristin Complex, known commercially as Synercid. The ribosome is composed of two ribonucleoprotein subunits, the 50S, and 30S. The 50S ribosome inhibitors inhibited protein synthesis.
CAS:
T22707
Formula:
C34H51N4O9S?CH3SO3
Molecular Weight:
787
Purity:
0.98
SMILES:
O=C(/C=C/[C@@H](C)[C@@H](C(C)C)OC(C1N(CC[C@H]1S(CC[NH+](CC)CC)(=O)=O)C(C2=COC(C3)=N2)=O)=O)NC/C=CC(C)=C[C@@H](O)CC3=O.CS([O-])(=O)=O

References

1. Herbst D A, Reddy K R. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection[J]. Expert opinion on investigational drugs, 2013, 22(10): 1337-1346. 2. Gao M, Nettles R E, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect[J]. Nature, 2010, 465(7294): 96-100.